Expression of MECOM is associated with unfavorable prognosis in glioblastoma multiforme
Authors Hou A, Zhao L, Zhao F, Wang W, Niu J, Li B, Zhou Z, Dongyuan Z
Received 6 September 2015
Accepted for publication 5 November 2015
Published 13 January 2016 Volume 2016:9 Pages 315—320
Checked for plagiarism Yes
Review by Single-blind
Peer reviewers approved by Dr Ram Prasad
Peer reviewer comments 3
Editor who approved publication: Professor Daniele Santini
Aiwu Hou,1,* Lizhen Zhao,1,* Fuzhen Zhao,2 Weiliang Wang,3 Jianyi Niu,1 Bingxuan Li,1 Zhongjin Zhou,1 Dongyuan Zhu4
1Department of Neurology, Yidu Central Hospital of Weifang City, 2Department of Orthopedics, People’s Hospital of Qingzhou City, 3Department of Psychiatrics, People’s Third Hospital of Weifang City, Weifang, 4Department of Medical Oncology, Shandong Cancer Hospital and Institute, Shandong Academy of Medical Sciences
*These authors contributed equally to this work
Background: MDS1 and EVI1 complex locus protein EVI1 (MECOM) is an oncogenic transcription factor in several kinds of cancers. However, the clinical significance of MECOM in glioblastoma multiforme (GBM) has not been well elucidated.
Patients and methods: Our study enrolled 86 resected samples of GBM in three medical centers. We detected the expression of MECOM in all the 86 samples by immunohistochemistry and compared the difference of MECOM mRNA between tumor tissues and adjacent tissues with real-time polymerase chain reaction. With immunoblotting, we detected the MECOM expression in different GBM cell lines. Moreover, we analyzed the correlation between MECOM expression and clinicopathologic factors with chi-square test, and evaluated the prognostic value of MECOM with univariate and multivariate analysis.
Results: In GBM tissue, the percentage of MECOM high expression is 41.9% (36/86). The mRNA of MECOM in tumor tissues is remarkably higher than that in adjacent tissues, indicating the oncogenic role of MECOM in GBM. MECOM exists in all the detected cell lines with different abundance. Moreover, MECOM is correlated with poorer overall survival rate (P=0.033) and can be identified as an independent prognostic factor in GBM (P=0.042).
Conclusion: MECOM could be considered as an independent prognostic factor in GBM, predicting it as a potential and promising molecular drug target.
Keywords: MECOM, glioblastoma multiforme, progression, prognosis
This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.Download Article [PDF] View Full Text [HTML][Machine readable]